Literature DB >> 18298483

Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome.

T Nakashima1, A Yokoyama, H Ohnishi, H Hamada, N Ishikawa, Y Haruta, N Hattori, K Tanigawa, N Kohno.   

Abstract

OBJECTIVES: Acute respiratory distress syndrome (ARDS) patients show high levels of circulating mucin including KL-6/MUC1 (soluble MUC1 mucin). Because cancer mucin can bind vascular endothelial cells and platelets via selectins, mucin-selectin interactions are reported to trigger platelet aggregation and intravascular coagulation. Therefore, we hypothesized that KL-6/MUC1 is involved in the pathogenesis of disseminated intravascular coagulation (DIC) in ARDS. The aim of the current study is to evaluate the association between circulating KL-6/MUC1 and DIC in ARDS patients.
DESIGN: Observational study with structured follow-up.
SETTING: Intensive care unit in Hiroshima University Hospital.
SUBJECTS: Fifty-six newly diagnosed patients with ARDS.
INTERVENTIONS: Circulating levels of KL-6/MUC1 were measured during diagnosis and serially measured during the clinical course along with indices of respiratory failure, inflammation, coagulation and fibrinolysis and multiple organ dysfunction.
RESULTS: Acute respiratory distress syndrome patients complicated with DIC showed significantly higher levels of serum KL-6/MUC1 than patients without DIC during the clinical course. Amongst the parameters analysed at diagnosis of ARDS, KL-6/MUC1 was an independent predictor for DIC complication. The baseline level of circulating KL-6/MUC1 at diagnosis of ARDS was significantly correlated with an increased DIC score following ARDS diagnosis. Using an optimum cutoff level of KL-6/MUC1 obtained by a receiver operating characteristic curve, the sensitivity and specificity for predicting future DIC development in ARDS patients were 88.9% and 55.3%, respectively.
CONCLUSIONS: These results suggest that KL-6/MUC1 is associated with DIC development in ARDS patients. Elevated levels of KL-6/MUC1 at diagnosis could be a predictor of DIC complication in ARDS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298483     DOI: 10.1111/j.1365-2796.2008.01929.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

Review 1.  Biomarkers in pediatric acute respiratory distress syndrome.

Authors:  Erin F Carlton; Heidi R Flori
Journal:  Ann Transl Med       Date:  2019-10

Review 2.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28

3.  Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study.

Authors:  Shunsaku Takahashi; Norimasa Miura; Tomomi Harada; ZhongZhi Wang; Xinhui Wang; Hideyuki Tsubokura; Yoshiaki Oshima; Junichi Hasegawa; Yoshimi Inagaki; Goshi Shiota
Journal:  J Transl Med       Date:  2010-10-22       Impact factor: 5.531

4.  What's in a Number? Platelet Count Dynamics as a Novel Mediator of Acute Respiratory Distress Syndrome Survival.

Authors:  Tiffanie K Jones; Nuala J Meyer
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

5.  Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.

Authors:  Shigeo Kawase; Noboru Hattori; Nobuhisa Ishikawa; Yasushi Horimasu; Kazunori Fujitaka; Osamu Furonaka; Takeshi Isobe; Seigo Miyoshi; Hironobu Hamada; Takashi Yamane; Akihito Yokoyama; Nobuoki Kohno
Journal:  Respir Res       Date:  2011-07-26

6.  A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.

Authors:  Maria Alimova; Eriene-Heidi Sidhom; Abhigyan Satyam; Moran Dvela-Levitt; Michelle Melanson; Brian T Chamberlain; Seth L Alper; Jean Santos; Juan Gutierrez; Ayshwarya Subramanian; Elizabeth Grinkevich; Estefania Reyes Bricio; Choah Kim; Abbe Clark; Andrew Watts; Rebecca Thompson; Jamie Marshall; Juan Lorenzo Pablo; Juliana Coraor; Julie Roignot; Katherine A Vernon; Keith Keller; Alissa Campbell; Maheswarareddy Emani; Matthew Racette; Silvana Bazua-Valenti; Valeria Padovano; Astrid Weins; Stephen P McAdoo; Frederick W K Tam; Lucienne Ronco; Florence Wagner; George C Tsokos; Jillian L Shaw; Anna Greka
Journal:  bioRxiv       Date:  2020-06-30

Review 7.  COVID-19: A review of therapeutic strategies and vaccine candidates.

Authors:  Vladislav Izda; Matlock A Jeffries; Amr H Sawalha
Journal:  Clin Immunol       Date:  2020-11-17       Impact factor: 3.969

8.  A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.

Authors:  Maria Kost-Alimova; Eriene-Heidi Sidhom; Abhigyan Satyam; Brian T Chamberlain; Moran Dvela-Levitt; Michelle Melanson; Seth L Alper; Jean Santos; Juan Gutierrez; Ayshwarya Subramanian; Patrick J Byrne; Elizabeth Grinkevich; Estefanía Reyes-Bricio; Choah Kim; Abbe R Clark; Andrew J B Watts; Rebecca Thompson; Jamie Marshall; Juan Lorenzo Pablo; Juliana Coraor; Julie Roignot; Katherine A Vernon; Keith Keller; Alissa Campbell; Maheswarareddy Emani; Matthew Racette; Silvana Bazua-Valenti; Valeria Padovano; Astrid Weins; Stephen P McAdoo; Frederick W K Tam; Luciene Ronco; Florence Wagner; George C Tsokos; Jillian L Shaw; Anna Greka
Journal:  Cell Rep Med       Date:  2020-10-29

Review 9.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

10.  Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.

Authors:  Neha Tabassum; Hua Zhang; Justin Stebbing
Journal:  Cell Rep Med       Date:  2020-11-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.